Bristol Myers Squibb purchased Nvidia's latest-generation computing systems to accelerate drug discovery and development. The pharmaceutical giant will integrate these chips to power AI-driven research operations. This investment scales the company's computational capacity. Practitioners can expect faster iteration cycles in molecular modeling and clinical trial simulations as high-performance hardware replaces legacy systems.